APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense oligonucleotides (ASO) Drug and siRNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Outlook and Growth Opportunities 2026

23 December 2025218 pages

Choose your research edition.

Industry ResearchAntisense oligonucleotides (ASO) Drug and siRNA Drug Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antisense oligonucleotides (ASO) Drug and siRNA Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antisense oligonucleotides (ASO) Drug and siRNA Drug market include Novartis, Novo Nordisk, Biogen, AstraZeneca, WAVElife, Therapeutics, The WhiteOak Group, Inc., Sylentis and Sirnaomics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antisense oligonucleotides (ASO) Drug and siRNA Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antisense oligonucleotides (ASO) Drug and siRNA Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market.

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Company

Novartis

Novo Nordisk

Biogen

AstraZeneca

WAVElife

Therapeutics

The WhiteOak Group, Inc.

Sylentis

Sirnaomics

Silence

Secarna

Sarepta Therapeutics

Quark Pharmaceuticals

ProQR

Miragen Therapeutics

Ionis

Genzyme

Exicure

Dicerna

Avidity Biosciences

Arrowhead

Alnylam

Akcea

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type

Antisense Oligonucleotides (ASO) Drug

siRNA Drug

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application

Chronic Liver Disease

Protein Deposition Disease

Single Gene Rare Disease

Others

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antisense oligonucleotides (ASO) Drug and siRNA Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antisense oligonucleotides (ASO) Drug and siRNA Drug key companies, revenue, market share, and recent developments.

3. To split the Antisense oligonucleotides (ASO) Drug and siRNA Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antisense oligonucleotides (ASO) Drug and siRNA Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antisense oligonucleotides (ASO) Drug and siRNA Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antisense oligonucleotides (ASO) Drug and siRNA Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense oligonucleotides (ASO) Drug and siRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense oligonucleotides (ASO) Drug and siRNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense oligonucleotides (ASO) Drug and siRNA Drug industry.

Chapter 3: Detailed analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antisense oligonucleotides (ASO) Drug and siRNA Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antisense oligonucleotides (ASO) Drug and siRNA Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends Table 2. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers Table 3. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges Table 4. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Company (2021-2026) Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Company Manufacturing Base & Headquarters Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company, Product Type & Application Table 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antisense Oligonucleotides (ASO) Drug Table 15. Significant Companies of siRNA Drug Table 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type (2021-2026) Table 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Chronic Liver Disease Table 22. Significant Companies of Protein Deposition Disease Table 23. Significant Companies of Single Gene Rare Disease Table 24. Significant Companies of Others Table 25. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application (2021-2026) Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application (2027-2032) Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Region (2021-2026) Table 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Region (2027-2032) Table 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Market Share by Country (2027-2032) Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 44. Novartis Recent Development Table 45. Novo Nordisk Company Information Table 46. Novo Nordisk Business Overview Table 47. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 49. Novo Nordisk Recent Development Table 50. Biogen Company Information Table 51. Biogen Business Overview Table 52. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 54. Biogen Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 59. AstraZeneca Recent Development Table 60. WAVElife Company Information Table 61. WAVElife Business Overview Table 62. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 64. WAVElife Recent Development Table 65. Therapeutics Company Information Table 66. Therapeutics Business Overview Table 67. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 69. Therapeutics Recent Development Table 70. The WhiteOak Group, Inc. Company Information Table 71. The WhiteOak Group, Inc. Business Overview Table 72. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 74. The WhiteOak Group, Inc. Recent Development Table 75. Sylentis Company Information Table 76. Sylentis Business Overview Table 77. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 79. Sylentis Recent Development Table 80. Sirnaomics Company Information Table 81. Sirnaomics Business Overview Table 82. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 84. Sirnaomics Recent Development Table 85. Silence Company Information Table 86. Silence Business Overview Table 87. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 89. Silence Recent Development Table 90. Secarna Company Information Table 91. Secarna Business Overview Table 92. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 94. Secarna Recent Development Table 95. Sarepta Therapeutics Company Information Table 96. Sarepta Therapeutics Business Overview Table 97. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 99. Sarepta Therapeutics Recent Development Table 100. Quark Pharmaceuticals Company Information Table 101. Quark Pharmaceuticals Business Overview Table 102. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 104. Quark Pharmaceuticals Recent Development Table 105. ProQR Company Information Table 106. ProQR Business Overview Table 107. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 109. ProQR Recent Development Table 110. Miragen Therapeutics Company Information Table 111. Miragen Therapeutics Business Overview Table 112. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 114. Miragen Therapeutics Recent Development Table 115. Ionis Company Information Table 116. Ionis Business Overview Table 117. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 119. Ionis Recent Development Table 120. Genzyme Company Information Table 121. Genzyme Business Overview Table 122. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 124. Genzyme Recent Development Table 125. Exicure Company Information Table 126. Exicure Business Overview Table 127. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 129. Exicure Recent Development Table 130. Dicerna Company Information Table 131. Dicerna Business Overview Table 132. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 134. Dicerna Recent Development Table 135. Avidity Biosciences Company Information Table 136. Avidity Biosciences Business Overview Table 137. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 139. Avidity Biosciences Recent Development Table 140. Arrowhead Company Information Table 141. Arrowhead Business Overview Table 142. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 144. Arrowhead Recent Development Table 145. Alnylam Company Information Table 146. Alnylam Business Overview Table 147. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 149. Alnylam Recent Development Table 150. Akcea Company Information Table 151. Akcea Business Overview Table 152. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 153. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 154. Akcea Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Image Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antisense Oligonucleotides (ASO) Drug Image Figure 8. siRNA Drug Image Figure 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type (2021-2032) Figure 12. Chronic Liver Disease Image Figure 13. Protein Deposition Disease Image Figure 14. Single Gene Rare Disease Image Figure 15. Others Image Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application (2021-2032) Figure 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotides (ASO) Drug
  • siRNA Drug
Applications
  • Chronic Liver Disease
  • Protein Deposition Disease
  • Single Gene Rare Disease
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Biogen
  • AstraZeneca
  • WAVElife
  • Therapeutics
  • The WhiteOak Group, Inc.
  • Sylentis
  • Sirnaomics
  • Silence
  • Secarna
  • Sarepta Therapeutics
  • Quark Pharmaceuticals
  • ProQR
  • Miragen Therapeutics
  • Ionis
  • Genzyme
  • Exicure
  • Dicerna
  • Avidity Biosciences
  • Arrowhead
  • Alnylam
  • Akcea

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Dynamics
  1. 2.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
  2. 2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers
  3. 2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges
  4. 2.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints
3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Company
  1. 3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Ranking (2024-2026)
  4. 3.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Product Type and Application
  6. 3.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antisense oligonucleotides (ASO) Drug and siRNA Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Type
  1. 4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Type Introduction
  2. 4.1.1 Antisense Oligonucleotides (ASO) Drug
  3. 4.1.2 siRNA Drug
  4. 4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type
  5. 4.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type (2021-2032)
5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Application
  1. 5.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Application Introduction
  2. 5.1.1 Chronic Liver Disease
  3. 5.1.2 Protein Deposition Disease
  4. 5.1.3 Single Gene Rare Disease
  5. 5.1.4 Others
  6. 5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application
  7. 5.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application (2021-2032)
6 Antisense oligonucleotides (ASO) Drug and siRNA Drug Regional Value Analysis
  1. 6.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032)
  7. 6.3.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032)
  16. 6.6.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Country, 2025 VS 2032
7 Antisense oligonucleotides (ASO) Drug and siRNA Drug Country-level Value Analysis
  1. 7.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  18. 8.3.5 Biogen Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 WAVElife
  26. 8.5.1 WAVElife Company Information
  27. 8.5.2 WAVElife Business Overview
  28. 8.5.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  30. 8.5.5 WAVElife Recent Developments
  31. 8.6 Therapeutics
  32. 8.6.1 Therapeutics Company Information
  33. 8.6.2 Therapeutics Business Overview
  34. 8.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  36. 8.6.5 Therapeutics Recent Developments
  37. 8.7 The WhiteOak Group, Inc.
  38. 8.7.1 The WhiteOak Group, Inc. Company Information
  39. 8.7.2 The WhiteOak Group, Inc. Business Overview
  40. 8.7.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  42. 8.7.5 The WhiteOak Group, Inc. Recent Developments
  43. 8.8 Sylentis
  44. 8.8.1 Sylentis Company Information
  45. 8.8.2 Sylentis Business Overview
  46. 8.8.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  48. 8.8.5 Sylentis Recent Developments
  49. 8.9 Sirnaomics
  50. 8.9.1 Sirnaomics Company Information
  51. 8.9.2 Sirnaomics Business Overview
  52. 8.9.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  54. 8.9.5 Sirnaomics Recent Developments
  55. 8.10 Silence
  56. 8.10.1 Silence Company Information
  57. 8.10.2 Silence Business Overview
  58. 8.10.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  60. 8.10.5 Silence Recent Developments
  61. 8.11 Secarna
  62. 8.11.1 Secarna Company Information
  63. 8.11.2 Secarna Business Overview
  64. 8.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  66. 8.11.5 Secarna Recent Developments
  67. 8.12 Sarepta Therapeutics
  68. 8.12.1 Sarepta Therapeutics Company Information
  69. 8.12.2 Sarepta Therapeutics Business Overview
  70. 8.12.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  72. 8.12.5 Sarepta Therapeutics Recent Developments
  73. 8.13 Quark Pharmaceuticals
  74. 8.13.1 Quark Pharmaceuticals Company Information
  75. 8.13.2 Quark Pharmaceuticals Business Overview
  76. 8.13.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  78. 8.13.5 Quark Pharmaceuticals Recent Developments
  79. 8.14 ProQR
  80. 8.14.1 ProQR Company Information
  81. 8.14.2 ProQR Business Overview
  82. 8.14.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  84. 8.14.5 ProQR Recent Developments
  85. 8.15 Miragen Therapeutics
  86. 8.15.1 Miragen Therapeutics Company Information
  87. 8.15.2 Miragen Therapeutics Business Overview
  88. 8.15.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  90. 8.15.5 Miragen Therapeutics Recent Developments
  91. 8.16 Ionis
  92. 8.16.1 Ionis Company Information
  93. 8.16.2 Ionis Business Overview
  94. 8.16.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  96. 8.16.5 Ionis Recent Developments
  97. 8.17 Genzyme
  98. 8.17.1 Genzyme Company Information
  99. 8.17.2 Genzyme Business Overview
  100. 8.17.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  102. 8.17.5 Genzyme Recent Developments
  103. 8.18 Exicure
  104. 8.18.1 Exicure Company Information
  105. 8.18.2 Exicure Business Overview
  106. 8.18.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  108. 8.18.5 Exicure Recent Developments
  109. 8.19 Dicerna
  110. 8.19.1 Dicerna Company Information
  111. 8.19.2 Dicerna Business Overview
  112. 8.19.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  114. 8.19.5 Dicerna Recent Developments
  115. 8.20 Avidity Biosciences
  116. 8.20.1 Avidity Biosciences Company Information
  117. 8.20.2 Avidity Biosciences Business Overview
  118. 8.20.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  120. 8.20.5 Avidity Biosciences Recent Developments
  121. 8.21 Arrowhead
  122. 8.21.1 Arrowhead Company Information
  123. 8.21.2 Arrowhead Business Overview
  124. 8.21.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  126. 8.21.5 Arrowhead Recent Developments
  127. 8.22 Alnylam
  128. 8.22.1 Alnylam Company Information
  129. 8.22.2 Alnylam Business Overview
  130. 8.22.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  132. 8.22.5 Alnylam Recent Developments
  133. 8.23 Akcea
  134. 8.23.1 Akcea Company Information
  135. 8.23.2 Akcea Business Overview
  136. 8.23.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  138. 8.23.5 Akcea Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst